Cetera Investment Advisers Has $1.12 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cetera Investment Advisers increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,770 shares of the biopharmaceutical company's stock after buying an additional 1,902 shares during the quarter. Cetera Investment Advisers' holdings in Alnylam Pharmaceuticals were worth $1,122,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. BOKF NA lifted its position in Alnylam Pharmaceuticals by 592.7% during the fourth quarter. BOKF NA now owns 381 shares of the biopharmaceutical company's stock worth $91,000 after purchasing an additional 326 shares during the period. Bridger Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 11.2% during the 4th quarter. Bridger Management LLC now owns 41,182 shares of the biopharmaceutical company's stock worth $9,691,000 after acquiring an additional 4,160 shares during the period. Brevan Howard Capital Management LP boosted its position in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Alnylam Pharmaceuticals by 32.7% during the 4th quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company's stock worth $1,509,000 after acquiring an additional 1,581 shares in the last quarter. Finally, Beck Bode LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $13,181,000. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Citigroup upped their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Finally, Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Trading Up 0.6%

NASDAQ ALNY traded up $1.61 during mid-day trading on Tuesday, reaching $291.57. 405,420 shares of the stock were exchanged, compared to its average volume of 916,663. The stock has a market cap of $38.02 billion, a P/E ratio of -134.47 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a one year low of $146.79 and a one year high of $304.39. The stock has a 50 day simple moving average of $259.09 and a 200-day simple moving average of $254.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period in the previous year, the business posted ($0.16) earnings per share. The company's quarterly revenue was up 20.2% on a year-over-year basis. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.